Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer

Antonio Jimeno, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biologic and clinical activity in patients with prostate cancer has been demonstrated In a Phase III, placebo-controlled setting by the suppression of markers of biochemical prostate cancer progression and a delay in time to disease progression. Atrasentan represents a new therapeutic option in the management of prostate cancer, especially in those patients with bone metastases. However, its precise role in other diseases such as ovarian cancer is yet to be defined.

Original languageEnglish (US)
Pages (from-to)419-427
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume5
Issue number3
DOIs
StatePublished - Jun 2005

Fingerprint

Prostatic Neoplasms
Neoplasms
Endothelins
Osteogenesis
Ovarian Neoplasms
Disease Progression
Cell Death
Therapeutics
Biomarkers
Placebos
Neoplasm Metastasis
Bone and Bones
atrasentan

Keywords

  • Atrasentan
  • Endothelin receptor A
  • Endothelin-1
  • Ovarian cancer
  • Prostate cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Atrasentan : A novel and rationally designed therapeutic alternative in the management of cancer. / Jimeno, Antonio; Carducci, Michael A.

In: Expert Review of Anticancer Therapy, Vol. 5, No. 3, 06.2005, p. 419-427.

Research output: Contribution to journalArticle

@article{97f416557e704f129d3a89cea46aa958,
title = "Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer",
abstract = "Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biologic and clinical activity in patients with prostate cancer has been demonstrated In a Phase III, placebo-controlled setting by the suppression of markers of biochemical prostate cancer progression and a delay in time to disease progression. Atrasentan represents a new therapeutic option in the management of prostate cancer, especially in those patients with bone metastases. However, its precise role in other diseases such as ovarian cancer is yet to be defined.",
keywords = "Atrasentan, Endothelin receptor A, Endothelin-1, Ovarian cancer, Prostate cancer, Targeted therapy",
author = "Antonio Jimeno and Carducci, {Michael A}",
year = "2005",
month = "6",
doi = "10.1586/14737140.5.3.419",
language = "English (US)",
volume = "5",
pages = "419--427",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Atrasentan

T2 - A novel and rationally designed therapeutic alternative in the management of cancer

AU - Jimeno, Antonio

AU - Carducci, Michael A

PY - 2005/6

Y1 - 2005/6

N2 - Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biologic and clinical activity in patients with prostate cancer has been demonstrated In a Phase III, placebo-controlled setting by the suppression of markers of biochemical prostate cancer progression and a delay in time to disease progression. Atrasentan represents a new therapeutic option in the management of prostate cancer, especially in those patients with bone metastases. However, its precise role in other diseases such as ovarian cancer is yet to be defined.

AB - Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biologic and clinical activity in patients with prostate cancer has been demonstrated In a Phase III, placebo-controlled setting by the suppression of markers of biochemical prostate cancer progression and a delay in time to disease progression. Atrasentan represents a new therapeutic option in the management of prostate cancer, especially in those patients with bone metastases. However, its precise role in other diseases such as ovarian cancer is yet to be defined.

KW - Atrasentan

KW - Endothelin receptor A

KW - Endothelin-1

KW - Ovarian cancer

KW - Prostate cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=21244445833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244445833&partnerID=8YFLogxK

U2 - 10.1586/14737140.5.3.419

DO - 10.1586/14737140.5.3.419

M3 - Article

C2 - 16001950

AN - SCOPUS:21244445833

VL - 5

SP - 419

EP - 427

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -